M Deppe1, M Abdelnaim2, T Hebel2, P M Kreuzer2, T B Poeppl2,3, B Langguth2, M Schecklmann2. 1. Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany. markus.deppe@medbo.de. 2. Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany. 3. Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Abstract
BACKGROUND/ OBJECTIVES: Repetitive transcranial magnetic stimulation (rTMS) has been established as an effective therapeutic intervention for the treatment of depression. Preliminary data suggest that the efficacy of rTMS is reduced in patients taking benzodiazepines (BZD). Here, we use real-world data from a large sample to investigate the influence of lorazepam on the effectiveness of rTMS. METHODS: From a retrospective cohort of clinically depressed patients that were treated with rTMS, we compared 176 patients not taking any BZD with 73 patients taking lorazepam with respect to changes in the Hamilton Depression Rating Scale (HRDS). RESULTS: Both groups improved during rTMS according to HRDS scores, but the amelioration of symptoms was significantly less pronounced in patients taking lorazepam (18% vs. 38% responders in the non-lorazepam group). We could not see any association of intake regimen of lorazepam with response in rTMS. CONCLUSION: Our observational study suggests that intake of lorazepam impedes the response to rTMS. The impact of lorazepam and other BZD on rTMS should receive more attention and be further investigated in prospective, hypothesis-based treatment studies to determine causal relationships between medication treatments and outcome. This could lead to specific recommendations for pharmacological treatment for depressed patients undergoing rTMS.
BACKGROUND/ OBJECTIVES: Repetitive transcranial magnetic stimulation (rTMS) has been established as an effective therapeutic intervention for the treatment of depression. Preliminary data suggest that the efficacy of rTMS is reduced in patients taking benzodiazepines (BZD). Here, we use real-world data from a large sample to investigate the influence of lorazepam on the effectiveness of rTMS. METHODS: From a retrospective cohort of clinically depressed patients that were treated with rTMS, we compared 176 patients not taking any BZD with 73 patients taking lorazepam with respect to changes in the Hamilton Depression Rating Scale (HRDS). RESULTS: Both groups improved during rTMS according to HRDS scores, but the amelioration of symptoms was significantly less pronounced in patients taking lorazepam (18% vs. 38% responders in the non-lorazepam group). We could not see any association of intake regimen of lorazepam with response in rTMS. CONCLUSION: Our observational study suggests that intake of lorazepam impedes the response to rTMS. The impact of lorazepam and other BZD on rTMS should receive more attention and be further investigated in prospective, hypothesis-based treatment studies to determine causal relationships between medication treatments and outcome. This could lead to specific recommendations for pharmacological treatment for depressed patients undergoing rTMS.
Authors: Alan F Schatzberg; A John Rush; Bruce A Arnow; Phillip L C Banks; Janice A Blalock; Frances E Borian; Robert Howland; Daniel N Klein; James H Kocsis; Susan G Kornstein; Rachel Manber; John C Markowitz; Ivan Miller; Philip T Ninan; Barbara O Rothbaum; Michael E Thase; Madhukar H Trivedi; Martin B Keller Journal: Arch Gen Psychiatry Date: 2005-05
Authors: Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Roger S McIntyre; Marie-Josée Filteau; Lawrence Martin; Simon Patry; Andre Carvalho; Danielle S Cha; Maxime Barakat; Maia Miguelez Journal: J Affect Disord Date: 2013-11-15 Impact factor: 4.839
Authors: Ulrich Reininghaus; Jan R Böhnke; UnYoung Chavez-Baldini; Robert Gibbons; Elena Ivleva; Brett A Clementz; Godfrey D Pearlson; Matcheri S Keshavan; John A Sweeney; Carol A Tamminga Journal: World Psychiatry Date: 2019-02 Impact factor: 49.548
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: T Hebel; M A Abdelnaim; M Deppe; P M Kreuzer; A Mohonko; T B Poeppl; R Rupprecht; B Langguth; M Schecklmann Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-07-03 Impact factor: 5.270